Tyra Biosciences Inc. (TYRA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Tyra Biosciences Inc. (TYRA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

15.96

0.86 (5.70%)

At close: Jan 14, 2025, 3:59 PM

15.94

-0.13%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	11.5
Market Cap	843.83M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.61
PE Ratio (ttm)	-9.91
Forward PE	n/a
Analyst	Buy

Ask	17.2
Volume	608,508
Avg. Volume (20D)	357,172
Open	15.24
Previous Close	15.10
Day's Range	15.11 - 16.57
52-Week Range	12.17 - 29.60
Beta	undefined

About TYRA

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondro...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 15, 2021

Employees 49

Stock Exchange NASDAQ

Ticker Symbol TYRA

Website https://www.tyra.bio

Analyst Forecast

According to 6 analyst ratings, the average rating for TYRA stock is "Buy." The 12-month stock price forecast is $30.5, which is an increase of 91.10% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-23.35%

Tyra Biosciences shares are trading lower. The com... Unlock content with Pro Subscription

11 months ago · Source

+29.29%

Tyra Biosciences shares are trading higher after the company announced $200 million in private placement financing.

News

1 month ago · 247wallst.com

Post-Election Insider Buying in These 6 Stocks Is Huge

24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.

2 months ago · benzinga.com

Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?

On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.

2 months ago · seekingalpha.com

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 ...

2 months ago · benzinga.com

BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug

BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines.